Alector (ALEC) Reports Q2 Loss, Tops Revenue Estimates

Group 1 - Alector reported a quarterly loss of $0.3 per share, better than the Zacks Consensus Estimate of a loss of $0.45, representing an earnings surprise of +33.33% [1] - The company posted revenues of $7.87 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 177.94%, compared to year-ago revenues of $15.08 million [2] - Alector has surpassed consensus EPS estimates four times over the last four quarters and topped consensus revenue estimates two times during the same period [2] Group 2 - Alector shares have declined approximately 24.3% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is -$0.49 on revenues of $2.83 million, and -$1.84 on revenues of $12.17 million for the current fiscal year [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Alector belongs, is currently in the top 41% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] - Alector currently holds a Zacks Rank 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6]